DRG Market Assessment 보고서

In the last 15 years, TNF-α inhibitors (AbbVie’s Humira, Amgen / Pfizer’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimzia) have transformed the treatment of ankylosing spondylitis (AS…

Myasthenia gravis (MG) is a rare neuromuscular disorder characterized by muscle weakness and fatigue. Clinical management of MG has historically focused on symptomatic treatment with the…

The availability of premium-priced branded agents prescribed in doublet, triplet, and quadruplet regimens, particularly Darzalex-based therapies, has had an impressive impact on the treatment of…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand which drugs…

Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss. The host immune system targets anagen hair follicles. The primary goal of treatment is…

TBI is a major cause of death and disability in the United States; DRG Epidemiology estimates that there were 250,000 moderate to severe TBI events diagnosed in U.S. hospitals / emergency rooms in…

While the incidence of gastric and GEJ adenocarcinoma continues to rise, efficacious treatment options, especially in the previously treated metastatic setting, remain limited. Cyramza (Eli Lilly)…

A growing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing forms of multiple sclerosis , the most prevalent form of MS. Nevertheless…

Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the entry of LAMAs (e.g., BI’s Spiriva) and…

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias. Based on our survey results, the U.S. reimbursement environment…

Clarivate Epidemiology’s coverage of hospital treated (HT) gram-negative infections (GNIs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

Clarivate Epidemiology’s coverage of hospital treated (HT) gram-negative infections (GNIs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…